Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-14
2008-09-16
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S396000, C514S397000
Reexamination Certificate
active
07425638
ABSTRACT:
The present invention provides compounds according to formula Ihaving the designations provided herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.
REFERENCES:
patent: 6734302 (2004-05-01), Kong et al.
patent: 363 061 (1990-04-01), None
patent: 0 433 682 (1991-06-01), None
patent: WO 92/03421 (1992-03-01), None
patent: WO 00/78725 (2000-12-01), None
patent: WO 02/20017 (2002-03-01), None
patent: WO 03/051359 (2003-06-01), None
Seung Hoon Cheon et al, Archives of Pharmacal Research, XP009036613,vol. 20, No. 2, pp. 138-143 (1997).
Haley Gregory Jay
Kong Norman
Liu Emily Aijun
Simonsen Klaus B.
Vu Binh Thanh
Hoffmann-La Roche Inc.
Johnston George W.
Rocha-Tramaloni Patricia S.
Stockton Laura L.
Wildman David E.
LandOfFree
Cis-imidazolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cis-imidazolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cis-imidazolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973948